Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDI01 in moderate or severe chronic graft-versus-host disease
NCT06169722Phase 2Active, not recruiting
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TDI01 in chronic graft-versus-host disease (cGVHD), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Feb 2024; status: active, not recruiting.
02
Drugs
TDI01
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06169722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169722.